Rate-limiting effects of cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol

Cancer Research

Volumn 62, Issue 8, 2002, Pages 2267-2271

  Nahta, Rita ^a   Iglehart, J Dirk ^b   Kempkes, Bettina ^c   Schmidt, Emmett V ^a,d  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; FLAVOPIRIDOL; PROTEIN P27; TRASTUZUMAB;

ARTICLE; BREAST CARCINOGENESIS; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; TITRIMETRY; TRANSCRIPTION REGULATION;

3T3 CELLS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; DRUG SYNERGISM; FLAVONOIDS; HUMANS; MICE; PIPERIDINES; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2;

EID: 0037089564     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
2. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
3. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway
4. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency
5. Specific protection against breast cancers by cyclin D1 ablation
6. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
7. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol
8. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
9. Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface
10. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
11. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
12. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation
13. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
14. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease, A property common to most cyclin-dependent kinase inhibitors?
15. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
16. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase 11 transcription in vivo
17. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol